Committee for Advanced Therapies (CAT) expert meeting on scientific and regulatory considerations for adeno-associated viral vector (AVV)-based gene therapy
EventHumanAdvanced therapiesInnovation
Croatian is available via eTranslation, the European Commission's machine translation service.
Translate to Croatian | Important information about machine translation
Date
- srijeda, 6 rujna 2017, Cijeli dan
Lokacija
- European Medicines Agency, Amsterdam, the Netherlands
An increasing number of recombinant AAV-based gene therapy medicinal products have entered clinical development in various therapeutic areas, including ophthalmology, neurology, haematology, metabolic disorders and muscular disorders. During this expert meeting, the CAT discussed with invited experts various scientific aspects of recombinant AAVs such as clinical grade manufacturing, virus-host interactions in animals and humans, immunity, persistence, toxicity and clinical development.